One probiotic, Escherichia coli Nissle (Mutaflor, Ardeypharm), is a nonpathogenic strain of E. coli that has been shown to be effective for both inducing remission in patients who have UC and maintaining remission for at least 1 year. Researchers have compared E. coli Nissle to mesalamine, which is the standard treatment for UC, and in a number Escherichia coli Nissle 1917 (EcN) bears a defect in its LPS biosynthesis leading to truncated variable oligosaccharide-antigen chains and a semi-rough phenotype. It is effectively inactivated by complement factors due to resolved serum resistance and is, therefore, safe as a probiotic strain, i.e. for the treatment of inflammatory Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negative strain isolated in 1917 by Alfred Nissle and it is the active component of microbial drug Mutaflor ® (Ardeypharm GmbH, Herdecke, Germany and EcN, Cadigroup, In Italy) used in many gastrointestinal disorder including diarrhea, uncomplicated diverticular disease and UC. It is the Methods and results: We treated stationary-phase E. coli MG1655 with a DNA-damaging fluoroquinolone and co-cultured the cells with probiotic E. coli Nissle following antibiotic removal. We found that E. coli Nissle reduced the survival of fluoroquinolone persisters and their progeny by over three orders of magnitude within 24 h. Caratteristiche. Il nome del batterio Escherichia coli Nissle 1917 ricorda le sue origini; esso fu infatti isolato per la prima volta dalle feci di un soldato tedesco nel 1917, dal ricercatore tedesco Alfred Nissle. Questo soldato - a differenza dei suoi compagni - non aveva sviluppato una diarrea infettiva (endemica per Shigella in quel momento), quando era di stanza nell'Europa sud-orientale Probiotics such as Escherichia coli Nissle 1917 and lactic acid bacteria are currently used to, or have been evaluated for use to, prevent or treat a range of intestinal maladies including inflammatory bowel disease, constipation, and colon cancer. Engineering these natural probiotics to produce immunomodulatory molecules may help to further .

e coli nissle 1917 probiotic